Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai Aricept "not approvable" for VaD

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Eisai/Pfizer's Alzheimer's therapy Aricept (donepezil) is "not approvable" for vascular dementia claim, FDA says July 3. FDA found that the application contained insufficient information to support an approval at this time, the firm said. Eisai plans to have discussions with FDA as to the next regulatory step. FDA's Peripheral & Central Nervous System Drugs Advisory Committee was scheduled to review the sNDA May 16, but the meeting was cancelled. At a March 2001 meeting, the committee had debated whether VaD was a distinct clinical entity. Aricept is the first agent to be filed for VaD, but Janssen's Reminyl (galantamine) and Novartis' Exelon (rivastigmine) are both in Phase III for the condition (1Pharmaceutical Approvals Monthly Oct. 1, 2002, p. 23

Related Content

Eisai Submits Aricept VaD sNDA; Study Criteria Endorsed By Committee





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts